VA adviser pushes to expand psychedelic therapy access for up to 2.1 million veterans
VA senior adviser Andrew Gradison wants capacity to offer psychedelic therapy to as many as 2.1 million veterans.
Objective Facts
Andrew Gradison, a senior adviser at the Veterans Health Administration, said at the Psychedelic Healthcare Forum in New York that the VA wants to build capacity to offer psychedelic therapies to as many as 2.1 million veterans with PTSD or depression, Politico and Psychedelic Alpha reported. That group is drawn from the 6.4 million veterans who regularly use VA care. Gradison said the VA has chosen ten sites, would start treating patients right away if drugs win FDA approval early next year, and expects demand to outrun supply. No psychedelic drug has been approved by the FDA for a mental illness, and Compass Pathways has said it expects a decision on its psilocybin therapy in the first half of 2027, according to Politico. Nocut News in South Korea carried the story mainly as a veteran suicide and regulation story.
Deep Dive
Gradison's remarks build on a string of federal moves this year. Donald Trump signed an executive order in April directing faster review of psychedelic drugs, including ibogaine, the Associated Press reported. In July the VA and HHS signed a memorandum of understanding to coordinate trials and train clinicians to give psychedelic medications if they are approved, according to Military Times. In August the VA opened a five-site psilocybin trial for treatment-resistant depression, The American Legion reported. VA Secretary Doug Collins has framed these steps as turning research into treatment. The 2.1 million figure describes eligibility, not near-term reach. Psychedelic Alpha reported that Gradison expects the first year to be a challenge even at roughly a thousand patients, and Politico quoted him saying demand will exceed supply. The FDA rejected MDMA-assisted therapy for PTSD in 2024, and the AP noted that ibogaine carries a risk of potentially fatal heart problems. Kyleanne Hunter of Iraq and Afghanistan Veterans of America told The National News Desk in July that rigorous trials are needed to measure risks as well as benefits, and that most evidence comes from former special operations troops. Support in Congress has come from both parties: Politico quoted Rep. Lou Correa, a Democrat, and Rep. Morgan Luttrell, a Republican who wants the executive order written into law. The next marker is the FDA. Gradison said the VA would begin treating patients if drugs become available in January or February, and Politico reported that Compass Pathways expects a psilocybin decision in the first half of 2027. Watch whether the VA names its ten sites, how it trains therapists to deliver treatment alongside psychotherapy, and whether Congress acts on Luttrell's push to codify the order after he retires in January.